Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Canntab Therapeutics Limited (C:PILL)

Business Focus: Alternative Medicine

Oct 18, 2021 07:30 am ET
Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.
TORONTO, Oct. 18, 2021 /PRNewswire/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has reached an agreement (the "Agreement") with 36Eight Technologies Inc. ("36Eight"), a growing bioinformatics pharmacological healthcare data and technology company, which has developed  a proprietary artificial intelligence and machine learning algorithm which augments the  underlying clinical data/knowledge to effici
Oct 18, 2021 07:30 am ET
Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.
TORONTO, Oct. 18, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has reached an agreement (the "Agreement") with 36Eight Technologies Inc. ("36Eight"), a growing bioinformatics pharmacological healthcare data and technology company, which has developed  a proprietary artificial intelligence and machine learning algorithm which augments the  underlying clinical data/knowledge to efficiently u
Jun 03, 2021 07:34 am ET
Canntab Announces the Early Exercise of $1,259,250 Warrants
TORONTO, June 3, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the receipt of C$1,259,250 in gross proceeds from the early exercise of  1,679,000 warrants into common shares (the "Warrants"). The Warrants were issued in the final week of May and each Warrant was exercised into 1 common share in the capital of the Company at $0.75. The Warrants were set to expire on late February or early March of 2
May 25, 2021 09:49 am ET
Canntab Mourns the Loss of Co-Founder
TORONTO, May 25, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces, with very heavy hearts, the passing of Jeffrey Ward Renwick, the Company's Co-Founder, Director and President.  After a long and difficult 15 month battle, Jeff succumbed to his lung cancer at the young age of 54 years. 
Mar 30, 2021 07:30 am ET
Canntab Receives Export License Approval from Health Canada
TORONTO, March 30, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.
Mar 08, 2021 11:05 pm ET
Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
3rd Patent Grant with Australia following the United States and Canada Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited Participation in Australia's Largest Cannabis Research Study TORONTO, March 9, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No. AU 2018210690 to Canntab, relate
Mar 03, 2021 09:43 am ET
Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.
Toronto, Ontario--(Newsfile Corp. - March 3, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE:TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2nd (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately $550,000.00. Canntab has now fulfilled 80% of the purchase amount contracted under the wholesale table purchase agreement entered into by the Company and MediPharm Labs in June, 2020.
Feb 17, 2021 07:30 am ET
Canntab Engages Independent Trading Group for Market Making Services
Toronto, Ontario--(Newsfile Corp. - February 17, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announced today that it has engaged Independent Trading Group Inc. ("ITG") to provide market-making services to the Company. ITG will trade the Company's common shares (the "Common Shares") on the Canadian Securities Exchange (the "CSE") and other marketplaces, as applicable, with the objective of maintaining a reasonable market and improving the liquidity of the Common Shares.
Feb 03, 2021 06:16 pm ET
Canntab Grants Options
Toronto, Ontario--(Newsfile Corp. - February 3, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab") announces that it has granted, in accordance with the Company's stock option plan, an aggregate of 50,000 options to purchase common shares of the Company to a consultant of the Company. Each option is exercisable at a price of $0.80 per share for a period of two years, expiring February 3, 2023.
Feb 01, 2021 09:06 am ET
IIROC Trade Resumption - PILL
VANCOUVER, BC, Feb. 1, 2021 /CNW/ - Trading resumes in:
Feb 01, 2021 08:27 am ET
Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets
TORONTO, Feb. 1, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian Intellectual Property Office ("CIPO") has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038. 
Feb 01, 2021 08:27 am ET
Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets
TORONTO, Feb. 1, 2021 /PRNewswire/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian Intellectual Property Office ("CIPO") has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038. 
Jan 29, 2021 07:30 am ET
IIROC Trading Halt - PILL
VANCOUVER, BC, Jan. 29, 2021 /CNW/ - The following issues have been halted by IIROC:
Dec 31, 2020 01:15 pm ET
Canntab Announces Closing of Convertible Debenture Private Placement
Toronto, Ontario--(Newsfile Corp. - December 31, 2020) - Canntab Therapeutics Limited. (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) ("Canntab" or the "Company"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the closing of a non-brokered private placement (the "Offering") of secured convertible debentures of the Company ("Convertible Debentures"), pursuant to which the Company issued Convertible Debentures for gross proceeds of $1,575,000 (the "Convertible Debentures"). The proceeds will be used to fund working capital for the Company, and for general corporate purposes.
Dec 01, 2020 07:30 am ET
Canntab Begins Delivery of Tablets to MediPharm
TORONTO, Dec. 1, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp.  (TSE:LABS.TO) (OTC:MEDIF).  Further to Canntab's press release dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million.  Canntab intends to complete and deliver the entir
Dec 01, 2020 07:30 am ET
Canntab Begins Delivery of Tablets to MediPharm
TORONTO, Dec. 1, 2020 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp.  (TSE:LABS.TO) (OTC:MEDIF).  Further to Canntab's press release dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million.  Canntab intends to complete and deliver th
Nov 16, 2020 09:37 am ET
Canntab Therapeutics Announces End of Supply and Distribution Agreements with Exactus
Toronto, Ontario--(Newsfile Corp. - November 16, 2020) -  Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis.
Oct 26, 2020 12:52 am ET
Canntab to Launch in Australia and Participate in Australia's Largest Cannabis Research Study
TORONTO, Oct. 26, 2020 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the impending launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. (ASX: CGB) ("CANN Global")
Oct 26, 2020 12:52 am ET
Canntab to Launch in Australia and Participate in Australia's Largest Cannabis Research Study
TORONTO, Oct. 26, 2020 /PRNewswire/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the impending launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. (ASX: CGB) ("CANN Global")
Oct 19, 2020 05:59 pm ET
Canntab Announces Closing of Purchases of Cannabis Processing Equipment and Leasehold Improvements
Toronto, Ontario--(Newsfile Corp. - October 19, 2020) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the previously announced asset purchase agreement with CMAX Technologies Inc. ("CMAX"), a related party of the Company has closed (the "CMAX Transaction"). Pursuant to the CMAX Transaction, Canntab has acquired certain cannabis-processing equipment and leasehold improvements (the "CMAX Assets") located at its 223 Riviera Drive, Markham, Ontario facility from CMAX Technologies Inc. for $1,018,000.
Sep 21, 2020 09:28 am ET
IIROC Trade Resumption - PILL
VANCOUVER, BC, Sept. 21, 2020 /CNW/ - Trading resumes in:
Sep 21, 2020 09:14 am ET
Canntab Granted 1st US Patent Covering Multi-Layer (Bi-Layer) Tablets
TORONTO, Sept. 21, 2020 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce that, pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,772,837 to Canntab, titled "Modified Release Multi-Layer Tablet Cannabinoid Formulations. The term of the patent expires on March 15, 2038.
Sep 17, 2020 09:43 am ET
IIROC Trading Halt - PILL
VANCOUVER, BC, Sept. 17, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 21, 2020 08:56 am ET
Canntab announces planned purchases of cannabis processing equipment and leasehold improvements
TORONTO, Aug. 21, 2020 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has entered into a binding asset purchase agreement to acquire certain cannabis-processing equipment and leasehold improvements (the "CMAX Assets") located at its 223 Riviera Drive, Markham, Ontario facility from CMAX Technologies Inc. ("CMAX"), a related party of the Company for $1,018,000 (the "CMAX Transaction").
Aug 19, 2020 07:30 am ET
Canntab Appoints Larry Latowsky as CEO
TORONTO, Aug. 19, 2020 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Larry Latowsky as CEO effective immediately.
Jun 02, 2020 11:29 am ET
IIROC Trade Resumption - PILL
VANCOUVER, BC, June 2, 2020 /CNW/ - Trading resumes in:
Jun 02, 2020 10:41 am ET
Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement
TORONTO, June 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs ("MediPharm") (TSX:LABS)(OTCQX: MEDIF)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products.
Jun 02, 2020 10:41 am ET
Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement
TORONTO, June 2, 2020 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs ("MediPharm") (TSX:LABS)(OTCQX: MEDIF)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products.
Jun 01, 2020 08:19 am ET
IIROC Trading Halt - PILL
VANCOUVER, June 1, 2020 /CNW/ - The following issues have been halted by IIROC:
May 15, 2020 07:30 am ET
Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer
TORONTO, May 15, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the appointment of Joshi Laxminarayan as Chief Scientific Officer (CSO). In his role as CSO, Mr. Laxminarayan will be responsible for directing Canntab's strategic research and partnership program, and overseeing the Company's ongoing manufacturing and distribution operations.
May 15, 2020 07:30 am ET
Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer
TORONTO, May 15, 2020 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the appointment of Joshi Laxminarayan as Chief Scientific Officer (CSO). In his role as CSO, Mr. Laxminarayan will be responsible for directing Canntab's strategic research and partnership program, and overseeing the Company's ongoing manufacturing and distribution operations.
May 11, 2020 07:30 am ET
Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference
TORONTO, May 11, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Mr. Larry Latowsky, Special Advisor and future Executive Chairman of the Board of Directors of the Company (pending Health Canada approval), will present via webcast at the Canaccord Genuity 4th Annual Cannabis Conference, on Tuesday, May 12, 2020, at 9:20 a.m. (EST).
May 11, 2020 07:30 am ET
Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference
TORONTO, May 11, 2020 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Mr. Larry Latowsky, Special Advisor and future Executive Chairman of the Board of Directors of the Company (pending Health Canada approval), will present via webcast at the Canaccord Genuity 4th Annual Cannabis Conference, on Tuesday, May 12, 2020, at 9:20 a.m. (EST).
Mar 16, 2020 07:30 am ET
Canntab Closes Final Tranche of Private Placement for Aggregate Proceeds of $3.7m
TORONTO, March 16, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has closed the final tranche of its previously announced non-brokered private placement (the "Private Placement") by issuing 1,291,000 units ("Units") at a price of $0.50 per Unit for gross proceeds of $645,500. Together with the funds raised under the first tranche of the Private Placement, the Company has received total gross pr
Mar 16, 2020 07:30 am ET
Canntab Closes Final Tranche of Private Placement for Aggregate Proceeds of $3.7m
TORONTO, March 16, 2020 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has closed the final tranche of its previously announced non-brokered private placement (the "Private Placement") by issuing 1,291,000 units ("Units") at a price of $0.50 per Unit for gross proceeds of $645,500. Together with the funds raised under the first tranche of the Private Placement, the Company has received total g
Mar 06, 2020 07:00 am ET
Canntab Announces Replacement of Advisor Warrants and Intention to Appoint Larry Latowsky as Director and Executive Chairman of the Board
TORONTO, March 6, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it intends to issue 500,000 common share purchase warrants (the "Replacement Warrants") to Larry Latowsky and that, subject to Health Canada approval, Canntab intends to appoint Larry Latowsky as a Director and Executive Chairman of the Board.
Mar 03, 2020 06:20 pm ET
Canntab Announces Cancellation of Options and Issuance of Warrants
Toronto, Ontario--(Newsfile Corp. - March 3, 2020) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that the Board of Directors passed a resolution to issue 1,300,000 warrants ("Warrants") to purchase common shares ("Common Shares") of the Company to employees, advisors and consultants of the Company. Each Warrant will entitle the holder to acquire one Common Share at a price of $0.60 until March 4, 2025.
Mar 02, 2020 09:06 am ET
IIROC Trade Resumption - PILL
VANCOUVER, March 2, 2020 /CNW/ - Trading resumes in:
Mar 02, 2020 08:15 am ET
Canntab Receives Health Canada Licence and Closes $3.08M Offering
Receives its Cannabis Standard Processing & Sales for Medical Purposes Licence Closes first tranche of its non-brokered private placement for gross proceeds of $3.08M Proceeds of the financing will be used to begin full scale manufacturing at its Markham facility, and to launch products across Canada and the United States TORONTO, March 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that on Frid
Feb 28, 2020 11:02 am ET
IIROC Trading Halt - PILL
VANCOUVER, Feb. 28, 2020 /CNW/ - The following issues have been halted by IIROC:
Feb 24, 2020 07:55 am ET
IIROC Trade Resumption - PILL
VANCOUVER, Feb. 24, 2020 /CNW/ - Trading resumes in:
Feb 24, 2020 06:30 am ET
Canntab Awarded Health Canada Cannabis Research Licence
TORONTO, Feb. 24, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that Health Canada has granted the Company a Cannabis Research Licence for the purpose of continuing research and development of the Company's growing line of next generation medical cannabis solutions at the Company's Markham Ontario Facility.
Feb 20, 2020 12:23 pm ET
IIROC Trading Halt - PILL
VANCOUVER, Feb. 20, 2020 /CNW/ - The following issues have been halted by IIROC:
Feb 06, 2020 12:38 pm ET
Canntab Announces Non-Brokered Private Placement
TORONTO, Feb. 6, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it is launching a private placement (the "Private Placement") of up to $2.5 million of units ("Units"), subject to the Company's over-allotment option to increase the size of  the Private Placement by up to an additional $1.5 million, at a price of $0.50 per Unit, with each Unit consisting of one common share and one full warrant to acq
Dec 23, 2019 01:30 am ET
Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status
The final step to obtain a licence to process Canntab's cannabis hard pill formulation, at its fully built out Markham, Ontario facility. Retains Larry Latowsky, former CEO of Katz Group Canada and its flagship holding Rexall, as an advisor in order to strengthen Canntab's commercialization efforts. TORONTO, Dec. 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces today the submission of the Company's Site Evidence
Nov 20, 2019 12:15 pm ET
Exactus, Inc. Enters into Supply & Distribution Agreement with Canntab Therapeutics to Produce Immediate and Extended Release Tablets
Exactus, Inc. (OTCQB:EXDI) (the “Company”), an industrial hemp farm operator and manufacturer of hemp-derived phytocannabinoid products, today announced that it has entered into a supply and distribution agreement with Canntab Therapeutics Limited...
Nov 20, 2019 11:27 am ET
IIROC Trade Resumption - PILL
VANCOUVER, Nov. 20, 2019 /CNW/ - Trading resumes in:
Nov 20, 2019 11:15 am ET
Canntab Achieves Key Milestone: Canntab Enters Into Supply & Distribution Agreements With Exactus for the Purchase of Hemp-Derived CBD Oil and the Distribution of Canntab's Hard Pill Formulations in t
Canntab will manufacture its hard pill formulations (made from CBD and other hemp derivatives) in a Florida facility operated by Exactus, using equipment supplied by Canntab Manufacturing is expected to begin near the end of Q1 2020 The agreements unlock a distribution channel to an estimated $1B+ CBD market in the U.S.1 Canntab's hard pill formulations include extended release, immediate release and oral disintegrating tablets made with a variety of hemp-derived cannabinoids in exacting dosages Canntab is also expected to manufacture its growing line of products at the Florida facility on a
Nov 20, 2019 08:23 am ET
IIROC Trading Halt - PILL
VANCOUVER, Nov. 20, 2019 /CNW/ - The following issues have been halted by IIROC:
Oct 08, 2019 07:30 am ET
Canntab to utilize the advanced BOSS extraction system from Word Class Extractions to further its own extraction capabilities
TORONTO, Oct. 8, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, today announced the signing of a binding Letter of Intent ("LOI") to establish a joint venture (the "Joint Venture") with World Class Extractions Inc. (CSE:PUMP) ("WCE"). Pursuant to the terms of the LOI, WCE will install certain extraction and processing systems (the "Systems") at Canntab's production facility in Markham, Ontario (the "Facility"). WCE is expecte
Oct 08, 2019 07:30 am ET
Canntab to utilize the advanced BOSS extraction system from Word Class Extractions to further its own extraction capabilities
TORONTO, Oct. 8, 2019 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, today announced the signing of a binding Letter of Intent ("LOI") to establish a joint venture (the "Joint Venture") with World Class Extractions Inc. (CSE:PUMP) ("WCE"). Pursuant to the terms of the LOI, WCE will install certain extraction and processing systems (the "Systems") at Canntab's production facility in Markham, Ontario (the "Facility"). WCE is
Aug 16, 2019 09:00 am ET
InvestmentPitch Media Video Discusses Canntab's Receipt of Initial Indication of Patentability for Immediate Release Cannabidiol Formulation - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation. The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not only patentable but also novel, non-obvious and useful.
Aug 15, 2019 07:00 am ET
Canntab Receives Initial Indication of Patentability for Immediate Release Cannabidiol Formulation
TORONTO, Aug. 15, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation (the "Immediate Release Formulation"). The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not only pa
Aug 15, 2019 07:00 am ET
Canntab Receives Initial Indication of Patentability for Immediate Release Cannabidiol Formulation
TORONTO, Aug. 15, 2019 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation (the "Immediate Release Formulation"). The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not
Aug 01, 2019 09:00 am ET
InvestmentPitch Media Video Discusses Canntab's Update of Significant Developments Including Hemp Cultivation and Gel Capsule Manufacturing - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - August 1, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has updated investors about significant developments. Canntab, with headquarters and R & D located in Markham, currently operates out of Cobourg, Ontario where the company has co-location and profit sharing agreements with its strategic partner, FSD Pharma Inc. (CSE:HUGE), a holder of both cultivating and processing licenses.
Jul 31, 2019 06:30 am ET
Canntab provides corporate update
Commercial batch manufacturing of oil-filled gel capsules to begin in Cobourg, leading to a Health Canada request for authorization to begin full scale production and sale. Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status. Cultivation at the hemp farm in Caledon advances with harvesting to begin next week. A pharmacist and drug formulation specialist has been hired to assist with our product applications to Health Canada. TORONTO, July 31, 2019 /CNW/ - Canntab Therapeutics Limited (CSE
Jul 31, 2019 06:30 am ET
Canntab provides corporate update
Commercial batch manufacturing of oil-filled gel capsules to begin in Cobourg, leading to a Health Canada request for authorization to begin full scale production and sale. Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status. Cultivation at the hemp farm in Caledon advances with harvesting to begin next week. A pharmacist and drug formulation specialist has been hired to assist with our product applications to Health Canada. TORONTO, July 31, 2019 /PRNewswire/ - Canntab Therapeutics Limit
Jun 24, 2019 12:58 pm ET
Marijuana Investor Magazine June/July 2019 Issue Now Available
ATLANTA, GA / ACCESSWIRE / June 24, 2019 / CannaInvestor Magazine, the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced today that it has published its June/July 2019 Issue of the U.S. and Canadian CannaInvestor Magazines. All digital magazines are free to the public.
Jun 24, 2019 12:25 pm ET
Canntab Therapeutics Featured in the Canadian Cannabis Investor Magazine
TORONTO, ON / ACCESSWIRE / June 24, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it is the featured company in the Canadian CannaInvestor Magazine June 2019 Issue. The Canadian CannaInvestor Magazine is the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and the financial media. The digital versio
May 31, 2019 09:00 am ET
InvestmentPitch Media Video Discusses Canntab's Term Sheet with Heritage Cannabis to Process Hemp into High Quality CBD Oil for Canntab's Gelcaps - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has signed a term sheet with Heritage Cannabis Holdings.
May 30, 2019 01:10 pm ET
May 30, 2019 11:54 am ET
Canntab signs term sheet with Heritage for processing hemp for sale of CBD filled gelcaps
- Canntab Makes Progress Towards Becoming Revenue-Generating in 2019 -
May 22, 2019 09:00 am ET
InvestmentPitch Media Video Discusses Canntab's Receipt of Cultivation Licence from Health Canada to Grow Industrial Hemp - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has received a cultivation licence from Health Canada to grow industrial hemp. Canntab intends to utilize the Hemp License to grow and cultivate its own supply of hemp biomass for the extraction of CBD and for the purpose of identifying high CBD strains to be used in future seasons.
May 21, 2019 07:30 am ET
Canntab Receives Cultivation Licence for Industrial Hemp
Enables Canntab to Leverage Properties in Saskatchewan and Ontario to Cultivate High Quality Hemp for the Extraction of Cannabidiol (CBD)
May 21, 2019 07:30 am ET
Canntab Receives Cultivation Licence for Industrial Hemp
Enables Canntab to Leverage Properties in Saskatchewan and Ontario to Cultivate High Quality Hemp for the Extraction of Cannabidiol (CBD)
May 01, 2019 08:30 am ET
Canntab Therapeutics Now Trading on the OTCQX Best Market
Canntab upgrades to the OTCQX Best Market for Better Investor Visibility
May 01, 2019 08:30 am ET
Canntab Therapeutics Now Trading on the OTCQX Best Market
Canntab upgrades to the OTCQX Best Market for Better Investor Visibility
May 01, 2019 07:00 am ET
OTC Markets Group Welcomes Canntab Therapeutics Ltd to OTCQX
NEW YORK, May 1, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Canntab Therapeutics Ltd (CSE: PILL; OTCQX: CTABF), a Canadian cannabis oral dosage formulation company engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has qualified to trade on the OTCQX® Best Market.  Canntab Therapeutics upgraded to OTCQX from the OTCQB® Venture Market.
Apr 24, 2019 09:10 am ET
InvestmentPitch Media Video Discusses Canntab Approaching Revenue under FSD Pharma's New "Sale for Medical Purposes" Cannabis License - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has advanced its revenue model following FSD Pharma's receipt of a "Sale for Medical Purposes" license. By virtue of Canntab's collaboration and profit sharing agreement with FSD Pharma (CSE:HUGE), this new license allows Canntab to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable Canntab to launch production and sales of its capsules.
Apr 23, 2019 08:30 am ET
Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada
- Opens the Door for Canadian and International Sales and White Labeling -
Apr 23, 2019 08:30 am ET
Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada
- Opens the Door for Canadian and International Sales and White Labeling -
Apr 22, 2019 08:30 am ET
FSD Pharma Receives Cannabis Sales License from Health Canada
- New license positions FSD to serve the growing medicinal use markets -
Mar 28, 2019 08:30 am ET
Canntab Therapeutics Announces Engagement of Relations Publiques Paradox Inc. for Investor Relations Services
Canntab Therapeutics Limited (CSE: PILL) (the “Company” or “Canntab”) is pleased to announce that, effective March 21, 2019, it has engaged Relations Publiques Paradox Inc. (“Paradox”) to provide investor relations services to the Company. Paradox...
Feb 28, 2019 07:00 am ET
Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and loan agreement (the “Agreement”) with FSD Pharma Inc. (“FSD”) and World Class Extractions...
Feb 19, 2019 11:30 pm ET
Canntab Provides Corporate Update
Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to provide an update on a number of significant developments, including that it has commenced converting a portion of its facility situated...
Jan 17, 2019 08:30 am ET
FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE: HUGE) (OTC: FSDDF) (FSE:...
Dec 21, 2018 09:00 am ET
Canntab & FSD Pharma Make Cannabis More Palatable for Doctors -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE: PILL) (TBF1.F). The...
Dec 13, 2018 08:00 am ET
Canntab Partners with Leading Surgeon to Conduct Pain Management Trial -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1),...
Dec 05, 2018 08:00 am ET
Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”), today announces the launch of a research partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, M.D. (Head of the Division of Lower Limb Reconstruction...
Nov 29, 2018 09:00 am ET
Canntab Nears Commercialization with Innovative Cannabis Tablets-- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing a key problem facing the medical cannabis industry:...
Nov 14, 2018 02:07 pm ET
Canntab Announces Correction to Press Release 
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) wishes to issue a correction to its press release disseminated earlier today, which incorrectly stated that its proposed instant release, extended release, flash melt...
Nov 14, 2018 07:41 am ET
Canntab Corporate Update
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) is a company with a clear vision of becoming the leader in solid oral dosage formulation of cannabis.  Their unique products offer advantages to the medical community,...
Oct 31, 2018 07:30 am ET
Canntab to Enter Medicinal Cannabis Market in Mexico
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) today announced the signing of a non-binding Letter of Intent (the “LOI”) with Labsco Promedic SA de CV of Monterrey, Mexico (“Labsco”) for the establishment of a...
Oct 22, 2018 09:10 am ET
InvestmentPitch Media Video Discusses Canntab Therapeutics and its Application to Become a Licensed Producer Under ACMPR with Health Canada - Video News Alert on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2018) -  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations with Health Canada. The License, if granted by Health Canada, would allow the company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility.
Oct 19, 2018 10:22 am ET
Canntab Files Application to Become Licensed Producer
Canntab Therapeutics Limited (CSE:PILL) (“Canntab” or the “Company”), a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the...
Oct 18, 2018 07:43 am ET
Canntab Files Application to Become Licensed Producer
Toronto, Ontario--(Newsfile Corp. - October 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the "License"), and that it received confirmation from Health Canada that its application had been received. The License, if granted by Health Canada, would allow the Company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility.
Oct 04, 2018 04:27 pm ET
Canntab Therapeutics, Extended Release Cannabis Tablets, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) - Jeff Renwick, CEO of Canntab Therapeutics speaks about their proprietary solid cannabis delivery system technology.
Oct 04, 2018 09:10 am ET
InvestmentPitch Media Video Discusses Canntab Therapeutics LOI With NewCanna of Colombia to Distribute Canntab Products in Select Countries - Video News Alert on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) -  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has Signed a non-binding Letter of Intent with NewCanna S.A.S. of Bogota, Colombia,
Sep 25, 2018 09:00 am ET
FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets per Day
Toronto, Ontario--(Newsfile Corp. - September 25, 2018) - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE: PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market. The manufacturing equipment consists of a fully GMP High output Tablet press capable of pressing more than 1,500,000 tablets per day, as well as blending machinery, large scale process and drying equipment and packaging equipment.
Sep 24, 2018 09:34 am ET
Canntab Added to CSE Composite Index
Toronto, Ontario--(Newsfile Corp. - September 24, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), is pleased to inform investors that effective September 21, 2018 the Company has been added to the Composite Index of the Canadian Securities Exchange as part of the CSE's quarterly rebalancing.
Sep 20, 2018 09:00 am ET
Canntab Sets New All-Time High Trading Prices and Volume
Toronto, Ontario--(Newsfile Corp. - September 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices of $1.74 and $1.41, respectively, on the Canadian Securities Exchange (the "CSE"). These numbers exceed the Company's previous all-time highs by 39.2% and 15.6%, which were also set earlier this week. In addition, the Company traded an aggregate of 1,583,326 Common Shares yesterday at a total dollar value of $2.06M, which constitutes its all-time high daily volume and exceeds the Company's previous highs, set on the Company's opening day of trading on April 20, 2018.
Sep 19, 2018 09:00 am ET
Canntab Exceeds All-Time High Trading Prices and Grants Options
Toronto, Ontario--(Newsfile Corp. - September 19, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices of $1.25 and $1.22, respectively, on the Canadian Securities Exchange (the "CSE"). This constitutes a 25% and 22% premium on the price of the Common Shares that were issued in the Company's private placement that closed concurrently with its reverse takeover in April. In addition, the Company traded an aggregate of 776,999 Common Shares yesterday, which represents the second highest daily volume in the Company's history, only being surpassed by the Company's opening day of trading on April 20, 2018.
Sep 18, 2018 09:29 am ET
Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials
Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), today announced the achievement of a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") through its wholly-owned subsidiary Emblem Cannabis Corporation (collectively, "Emblem").
Sep 18, 2018 09:29 am ET
Canntab Signs Collaboration and Profit Sharing Agreement with FSD Pharma for Production and Market of Oral Dose Delivery Platforms
Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement) (OTC Pink: FSDDF) (FRA: 0K9) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction").
Sep 11, 2018 09:28 am ET
Canntab Therapeutics Launches Capital Markets Communications Strategy
Toronto, Ontario--(Newsfile Corp. - September 11, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that, effective today, the Company will be increasing its level of engagement with shareholders and with potential retail and institutional investors. Accordingly, it has retained the services of Mackie Research Capital Corporation ("Mackie Research") to act as financial advisor to the Company and the services of Hybrid Financial Limited ("Hybrid") to assist the Company with Investor Relations by effectively communicating the Company's message to an increasingly broad range of investment advisors across Canada.
Jul 16, 2018 08:30 am ET
Canntab Engages Industry Leader Lorne Gertner as Consultant
TORONTO, July 16, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that it has engaged Lorne Gertner, one of the world's foremost investors in the cannabis industry and one of its trailblazing pioneers, as a strategic consultant.  Mr. Gertner has significant experience on the boards of a number of publicly traded cannabis companies, including Hiku Brands Company, and has developed a global network of contacts in the cannabis industry along with a deep understanding
Jul 11, 2018 09:10 am ET
InvestmentPitch Media Video Discusses Canntab Therapeutics LOI with FSD Pharma to Obtain License to Process and Sell Cannabis Based Products - Video News Alert on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2018) - Canntab Therapeutics (CSE: PILL), a cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has entered into a non-binding letter of intent with FSD Pharma Inc. (CSE:HUGE). FSD Pharma, through its wholly-owned subsidiary FV Pharma, is a licensed producer under the Access to Cannabis for Medical Purposes Regulations.
Jul 09, 2018 08:25 pm ET
Canntab announces collaboration and profit sharing agreement with FSD Pharma to produce and market oral dose delivery platforms
TORONTO, July 9, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with FSD Pharma Inc. (CSE: HUGE) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and wil
Jun 20, 2018 09:44 am ET
Canntab Announces Launch of Innovative Hemp Oil Capsules
Toronto, Ontario--(Newsfile Corp. - June 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") is pleased to announce the Health Canada approval and launch of the first of its '420 Therapeutics' brand of Cannabis wellness products: Hemp Oil Gel Capsules. Made from purified organic hemp seed oil, the Hemp Oil Gel Capsules are an easy and convenient way to enjoy the health benefits of hemp oil.
Jun 14, 2018 07:10 pm ET
Canntab Announces Director Resignation
Toronto, Ontario--(Newsfile Corp. - June 14, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") announces that Sheldon Inwentash has resigned from the Company's Board of Directors to pursue other opportunities. Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, "I would like to thank Sheldon for his valuable contributions to the Company and, on behalf of the Board, I wish him every success in his future endeavours."
Jun 06, 2018 08:40 am ET
Canntab: Advancing Cannabinoid Research in Australia -- CFN Media
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Canntab Therapeutics Ltd. (CSE:PILL) (CNSX:PILL) (PILL.CN) and its...
Jun 01, 2018 06:21 pm ET
CORRECTING and REPLACING – Canntab Brings Pharma Standards to Medical Cannabis -- CFN Media
In a release issued yesterday under the same headline by CFN Media, please be advised that a quote has been removed from the first paragraph. Additionally, the stock exchange for Emblem Corp. in the ninth paragraph should be TSX-V rather CSE,...
May 31, 2018 08:42 am ET
Canntab Brings Pharma Standards to Medical Cannabis -- CFN Media
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering CannTab Therapeutics Inc. (CSE:PILL) (CNSX:PILL) (PILL.CN) and its...
May 25, 2018 10:03 am ET
Canntab Therapeutics Files 2 New Canadian Patent Applications Related to Pharmaceutical Cannabis
Toronto, Ontario--(Newsfile Corp. - May 25, 2018) - Canntab Therapeutics Limited (CSE: PILL) (formerly Telferscot Resources Inc.) ("Canntab" or the "Company") is pleased to announce that it continues to expand its extensive intellectual property portfolio through the recent filing of 2 additional Canadian patent applications. Canntab's portfolio now includes 13 patent applications in Canada, the United States and internationally. These filings build on Canntab's growing intellectual property portfolio, which already included patent applications and trademark applications in the United States and Canada. The new Canadian patent applications that were filed pertain to a variety of Canntab's innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including Sustained Release Cannabinoid Formulations and Sustained Release Cannabinoid Pellets.
May 17, 2018 01:30 am ET
Canntab Appoints Bob Woloschuk to Advisory Board
Toronto, Ontario--(Newsfile Corp. - May 17, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") is pleased to announce the appointment of Bob Woloschuk to its Advisory Board. Bob has over 20 years of pharmaceutical executive experience and has a keen eye for licensing opportunities, both in Canada and in international markets.
May 15, 2018 05:37 pm ET
Canntab Provides Clarification on CFN Media Engagement
Toronto, Ontario--(Newsfile Corp. - May 15, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") wishes to provide clarification on the terms of its engagement of CFN Media Group ("CFN Media"), which were previously announced in a news release disseminated by CFN Media on May 15, 2018. Canntab wishes to clarify that CFN Media was engaged to provide investor relations services. The terms of the engagement require Canntab to pay CFN Media the amount of USD $5,000 per month for a period of three months commencing today, with neither party being under an obligation to extend the agreement beyond the initial three month term.
May 15, 2018 09:00 am ET
Canntab Therapeutics Engages CFN Media to Build New Investor Audience
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that Canntab Therapeutics Ltd. (CSE:PILL) (CNSX:PILL) (PILL.CN) has engaged CFN Media to conduct a...
May 14, 2018 09:21 am ET
Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation
Paris, Ontario--(Newsfile Corp. - May 14, 2018) - Emblem Corp. (TSXV: EMC) (TSXV: EMC.WT) ("Emblem" or the "Company") and Canntab Therapeutics Limited (CSE: PILL) ("Canntab") are pleased announce to receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the "Sustained Release Product" or the "Product"), which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab's partnership to develop long-acting cannabis formulations.
May 14, 2018 08:00 am ET
Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation
Emblem Corp. (TSX-V:EMC) (TSX-V:EMC.WT) (“Emblem” or the "Company") and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of Health Canada approval for research and development activities on oral sustained...
Apr 27, 2018 09:20 am ET
CSE New Listing - Canntab Therapeutics Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2018) - Canntab Therapeutics (CSE: PILL) is one of the latest new listings on the Canadian Securities Exchange. Markham, Ontario-based Canntab is a Canadian cannabis oral dosage formulation company, en-gaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids.
Apr 26, 2018 09:00 am ET
Canntab Therapeutics Files 11 Patent Applications Related to Pharmaceutical Cannabis
Toronto, Ontario--(Newsfile Corp. - April 26, 2018) - Canntab Therapeutics Limited (CSE: PILL) (formerly Telferscot Resources Inc.) ("Canntab" or the "Company") is pleased to announce that it continues to expand its extensive intellectual property portfolio through the recent filing of 3 additional US patent applications and 1 international (Patent Cooperation Treaty or "PCT") application. Canntab's portfolio now includes 11 patent applications in the United States and internationally. These filings, which include 7 non-provisional US patent application and 4 PCT patent applications, build on Canntab's growing intellectual property portfolio, which already included 7 provisional US patent applications and 10 trademark applications in the United States and Canada. The patent applications that were filed pertain to a variety of Canntab's innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including:
Apr 24, 2018 09:44 am ET
Canntab Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - April 24, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") is pleased to announce two recent developments: (i) an update on its application for a Dealer's License with Health Canada; and (ii) its Australian joint venture partner has obtained a license to import medical cannabis products.
Apr 19, 2018 10:09 am ET
Canntab to Commence Trading on CSE on 4/20
Toronto, Ontario--(Newsfile Corp. - April 19, 2018) - Canntab Therapeutics Limited (CSE: PILL) (formerly Telferscot Resources Inc.) ("Canntab" or the "Company") is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the "CSE") at the opening of the market on Friday, April 20, 2018 under the stock symbol "PILL".